how to purchase genocea stock

How to buy shares in Genocea Biosciences.

• Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
• Open your brokerage account. Complete an application with your details.
• Confirm your payment details. Fund your account.
• Research the stock. Find the stock by name or ticker symbol – GNCA – and research it before deciding if it's a good investment for you.
• Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a ...

Full Answer

Should you buy Genocea Biosciences stock?

There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Genocea Biosciences stock. View analyst ratings for Genocea Biosciences or view top-rated stocks.

Is Genocea (GNCA) stock about to get delisted from the NASDAQ?

In addition to this, Genocea Biosciences has announced that it will be voluntarily delisting shares of GNCA stock from the Nasdaq Capital Market. It intends to file a Form 25 with the U.S. Securities and Exchange Commission (SEC) to effect this delisting on June 2.

Where can I buy shares of GNCA?

Shares of GNCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.

About Genocea Biosciences

Genocea Biosciences, Inc. engages in the development and commercialization of cancer vaccines. The firm uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses.

Genocea Biosciences (NASDAQ:GNCA) Frequently Asked Questions

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Genocea Biosciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Genocea Biosciences stock. View analyst ratings for Genocea Biosciences or view top-rated stocks.

What is Genocea Biosciences?

(NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, President and Chief Executive Officer, will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference on Tuesday, April 13th at 2:15 P.M. ET. A live webcast of the presentation will be available "Events and Presentations" tab of the investor relations section of the Genocea website at http://ir.genocea.com. Following the conclusion of the conference, the presentation will remain archived on the Genocea website for approximately 90 days. About Genocea Biosciences, Inc.Genocea’s mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our proprietary ATLAS™ platform comprehensively profiles each patient’s T cell responses to potential targets, or antigens, on that patient’s tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, Inhibigens™, that drive pro-tumor immune responses. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine for which we are conducting a Phase 1/2a clinical trial and GEN-011, our adoptive T cell therapy using neoantigen-targeted peripheral cells for which we are commencing a Phase 1/2a clinical trial. In addition to our two clinical programs, we are conducting research in several areas where we believe ATLAS could be a key tool in identifying meaningful therapies. To learn more, please visit https://www.genocea.com. Investor Contact:Dan [email protected]

When will Genocea have clinical data?

The company expects to have initial efficacy data from a patient subset late in the fourth quarter of 2021 or the first quarter of 2022.